CEBPA and acute myeloid leukemia: One of this achievements was the delineation of a “very favorable” AML subgroup composed of patients with inv(16)/t(16;16) or biallelic CEBPA mutations, and a “very adverse” AML subgroup composed of patients with TP53 mutations and a complex karyotype (20).